This Plain Language Summary of Publication article (PLSP) from Future Oncology explains the ELM-2 study. The study looked at how well the medicine odronextamab works for treating follicular lymphoma, a type of blood cancer. Follicular lymphoma affects B cells, a type of white blood cell, and can cause swollen lymph nodes.
Visit the site using this link to read the article.
This PLSP is based on two articles:
- ‘Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma’’ published in Annals of Oncology
- ‘Health-related quality of life with odronextamab monotherapy for relapsed/refractory follicularlymphoma in the ELM-2 study’ published in Clinical Lymphoma, Myeloma & Leukemia
Visit Annals of Oncology using the link to read the original article.
Visit Clinical Lymphoma, Myeloma & Leukemia using the link to read the original article.